Roche’s Ocrevus Achieves Near-Complete Reduction of Relapse, Lesions in MS

Published: Apr 18, 2024 By Tristan Manalac

Roche_iStock, JHVEPhoto

Pictured: Roche Diagnostics’ building in California/iStock, JHVEPhoto 

Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.

Through 48 weeks of follow-up, subcutaneous Ocrevus resulted in the “near-complete suppression of relapse activity,” according to the announcement, which detailed that 97.2% of treated patients had no relapse during the study’s treatment phase.

Magnetic resonance imaging also showed that most patients did not have T1 gadolinium-enhancing lesions and that there were no new or enlarging T2 lesions. Both lesion types are indicators of disease burden and suggest active inflammation.

An exploratory analysis also found that 92.3% of patients were satisfied or very…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks